FDA, NIH collaborate on AE reporting

Share this article:

The FDA and the NIH have agreed to develop a harmonized adverse event (AE) reporting mechanism for consumers, health professionals, investigators, sponsors and other parties to electronically submit reports.

The project is aimed at developing a “Rational Questionnaire” and electronic prototype system for reporting. The questionnaire is intended to be an “interactive help system” that will assist AE reporters in determining which data need to be submitted and to whom. The prototype system will allow the agencies to test the feasibility of a central, federal web-based portal to provide direct, seamless, online submission of adverse event reports to appropriate agencies.

A harmonized reporting system would reduce the amount of reporting by clinical investigators, according to the MOU. Currently investigators must submit separate AE reports to multiple agencies using different forms.

“Oversight bodies and agencies receiving this information are often faced with tremendous volumes of data reported in idiosyncratic ways, which often frustrates efforts to conduct meaningful aggregations and analyses of data, or to cull from reports information key to important safety concerns,” the MOU explains.

A joint Federal Adverse Event Task Force has been formed and they are tasked with developing a consensus standard for adverse event reporting called the Basal Adverse Event Report. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...